Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease.
Name:
PIIS1525730416302273.pdf
Size:
418.6Kb
Format:
PDF
Description:
Full text, Open Access Article
Authors
Socinski, MKaye, F
Spigel, D
Kudrik, F
Ponce, S
Ellis, P
Majem, M
Lorigan, Paul C
Gandhi, L
Gutierrez, M
Nepert, D
Corral, J
Ares, L
Affiliation
Division of Hematology/Oncology, Univeristy of Pittsburgh Cancer Institute, Pittsburgh, PAIssue Date
2017-01
Metadata
Show full item recordAbstract
This trial assessed the safety and efficacy of LM in combination with carboplatin/etoposide therapy compared to carboplatin/etoposide treatment alone in patients with previously untreated extensive-disease small-cell lung cancer (ED-SCLC).Citation
Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease. 2017, 18(1):68-76.e2 Clin Lung CancerJournal
Clinical Lung CancerDOI
10.1016/j.cllc.2016.09.002PubMed ID
28341109Type
ArticleLanguage
enISSN
1938-0690ae974a485f413a2113503eed53cd6c53
10.1016/j.cllc.2016.09.002